Lawrence P. Carter, Ph.D.
Affiliations: | Jazz Pharmaceuticals, Palo Alto, CA, United States |
Area:
Human behavioral pharmacologyGoogle:
"Lawrence Carter"Mean distance: 16.17 (cluster 29) | S | N | B | C | P |
Parents
Sign in to add mentor| Charles Patrick France | grad student | 2005 | UT Health San Antonio | |
| (*Discriminative stimulus and behavioral effects of gamma-hydroxybutyrate.) | ||||
| Roland Griffiths | post-doc | Johns Hopkins | ||
| Miriam Z. Mintzer | post-doc | 2005-2007 | Johns Hopkins Medical School | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zomorodi K, Chen D, Lee L, et al. (2020) A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. Clinical Pharmacology in Drug Development |
| Strollo PJ, Malhotra A, Strohl K, et al. (2020) 0772 Effects Of Solriamfetol On 24-hour Blood Pressure Patterns In Participants With Excessive Daytime Sleepiness Associated With Narcolepsy Sleep. 43: A293-A293 |
| Strollo PJ, Malhotra A, Strohl K, et al. (2020) 0693 Effects Of Solriamfetol On 24-hour Blood Pressure Patterns In Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Sleep. 43: A264-A264 |
| Schweitzer PK, Mayer G, Rosenberg R, et al. (2019) P004 Solriamfetol for excessive daytime sleepiness in obstructive sleep apnoea: a randomised controlled trial Bmj Open Respiratory Research. 6 |
| Black J, Dauvilliers Y, Plazzi G, et al. (2019) P003 Randomised, placebo-controlled study of solriamfetol for excessive daytime sleepiness in narcolepsy types 1/2 Bmj Open Respiratory Research. 6 |
| Malhotra A, Strohl KP, Carter LP, et al. (2019) 0618 Weight Change Associated with Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy or Obstructive Sleep Apnea Sleep. 42: A246-A246 |
| Strollo PJ, Schwab R, Hedner J, et al. (2019) 0570 Dose Titration Of Solriamfetol In Participants With Obstructive Sleep Apnea From A 6-week Randomized-withdrawal Trial Sleep. 42: A227-A227 |
| Lammers G, Bogan R, Schweitzer P, et al. (2019) Thresholds for clinically meaningful changes on the epworth sleepiness scale and maintenance of wakefulness test sleep latency Sleep Medicine. 64: S210 |
| Carter LP, Henningfield JE, Wang YG, et al. (2018) A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. Journal of Psychopharmacology (Oxford, England). 269881118796814 |
| Baladi MG, Forster MJ, Gatch MB, et al. (2018) Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. The Journal of Pharmacology and Experimental Therapeutics |